Indonesia: COVID-19 vaccines market revenue 2028

In 2022, the coronavirus (COVID-19) vaccine market in Indonesia generated an annual revenue of around 670 million U.S. dollars, indicating a sharp decline compared to the previous year. The Statista Health Market Outlook estimated the revenue of the market would continue to decrease and reach around 130 million U.S. dollars by 2028.

Revenue of the COVID-19 vaccines market in Indonesia from 2021 to 2022 (in million U.S. dollars)

Characteristic	Revenue in million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Market values represent revenues paid to primary vendors at manufacturer price level either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), enterprises (B2B) as well as governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

A detailed methodology can be found in the Statista Market Outlook.

Citation formats